Jennison Health Sciences’ vast analytical resources and thoughtful approach combine for a bold but appealing healthcare offering.
PGIM Jennison Health Sciences C PHLCX
- NAV / 1-Day Return 19.12 / +0.95 %
- Total Assets 1.9 Bil
-
Adj. Expense Ratio
1.980%
- Expense Ratio 1.980%
- Distribution Fee Level Average
- Share Class Type Level Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield —
- Turnover 64%
USD | NAV as of Jul 27, 2024 | 1-Day Return as of Jul 27, 2024, 12:00 AM GMT+0
Morningstar’s Analysis PHLCX
Will PHLCX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 54.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 13.90 | 249.6 Mil | Healthcare |
Merck & Co Inc | 8.00 | 143.7 Mil | Healthcare |
Amgen Inc | 4.89 | 87.8 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 4.86 | 87.3 Mil | Healthcare |
UnitedHealth Group Inc | 4.60 | 82.7 Mil | Healthcare |
Novo Nordisk A/S ADR | 4.33 | 77.8 Mil | Healthcare |
Humana Inc | 3.99 | 71.6 Mil | Healthcare |
Boston Scientific Corp | 3.49 | 62.6 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 3.37 | 60.4 Mil | Healthcare |
Intuitive Surgical Inc | 3.26 | 58.5 Mil | Healthcare |